menu

Research into Parkinson’s Disease has been stymied in recent years due to an increase in placebo response rate among patients in phase III trials. Lynne Hughes, head of Quintiles Neurology Center of Excellence, recently completed a study of Parkinson’s Phase III trials to understand the causes of this placebo effect and to identify strategies to mitigate this risk in future trials. Lynne and her team presented these findings at ADPD2015, the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders in Nice, France.

Topics in this blog post: Clinical Trials, Biopharma, Neurology
About The Author

Vice President and Head, Neurology Center of Excellence

Recent thinking: Faster recruiting for rare disease research